Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | TARDBP | Q13148 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509587 | 1.00 | KMT2A (0.42) | KMT2AALOX15BLMPMP22DPP4 | |
| Hydrochloric Acid SCHEMBL3676279 | 0.98 | KMT2A (0.41) | KMT2AALOX15BLMPMP22DPP4 | |
| Hydrochloric Acid SCHEMBL3676282 | 0.98 | KMT2A (0.41) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL4952904 | 0.88 | GRM8 (0.43) | BLMDPP4DPP8DPP9 | |
| SCHEMBL4952914 | 0.88 | GRM8 (0.43) | BLMDPP4DPP8DPP9 | |
| SCHEMBL6753730 | 0.80 | GSR (0.43) | DPP4DPP8DPP9 | |
| SCHEMBL902368 | 0.79 | PTGS1 (0.36) | — | |
| SCHEMBL27662491 | 0.75 | ALOX15 (0.39) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL4955709 | 0.72 | CTSK (0.34) | — | |
| SCHEMBL10411481 | 0.71 | ALPI (0.49) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1965783-B1 | TREATMENT OF TYPE 2 DIABETES WITH A COMBINATION OF DPIV INHIBITOR AND METFORMIN OR THIAZOLIDINEDIONE | ROYALTY PHARMA COLLECTION TRUST (US) | 2013-06-19 | — | — | EP | claimed |
| US-20100216800-A1 | Treatment of Type 2 Diabetes With a Combination of DPIV Inhibitor and Metformin or Thiazolidinedione | ROYALTY PHARMA FINANCE TRUST | 2010-08-26 | — | — | US | claimed |
| US-20090186818-A1 | Therapeutic Method for Glycaemic Control | PROSIDION LIMITED (GB) | 2009-07-23 | — | — | US | claimed |
| CN-101365434-A | Treatment of type II diabetes using a combination of a DPIV inhibitor and metformin or a thiazolidinedione | PROSIDION LTD (GB) | 2009-02-11 | — | — | CN | claimed |
| EP-2010217-A2 | THERAPEUTIC METHOD FOR GLYCAEMIC CONTROL | Prosidion Limited (GB) | 2009-01-07 | — | — | EP | claimed |
| EP-1965783-A1 | TREATMENT OF TYPE 2 DIABETES WITH A COMBINATION OF DPIV INHIBITOR AND METFORMIN OR THIAZOLIDINEDIONE | Prosidion Limited (GB) | 2008-09-10 | — | — | EP | claimed |
| EP-1528931-B1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR DECREASING THE RATE OF CHRONIC WEIGHT GAIN | PROSIDION LTD (GB) | 2008-05-07 | — | — | EP | claimed |
| US-7368576-B2 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2008-05-06 | — | — | US | claimed |
| EP-1399471-B1 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2008-01-30 | — | — | EP | claimed |
| CN-101095675-A | Dipeptidyl peptidase IV effectors | PROBIODRUG AG (GB) | 2008-01-02 | — | — | CN | claimed |
| JP-2004521149-A | — | — | 2004-07-15 | — | — | JP | claimed |
| EP-1416932-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | Probiodrug AG (DE) | 2004-05-12 | — | — | EP | claimed |
| EP-1399470-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | Probiodrug AG (DE) | 2004-03-24 | — | — | EP | claimed |
| EP-1399471-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | Probiodrug AG (DE) | 2004-03-24 | — | — | EP | claimed |
| US-20030176357-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROSIDION LIMITED (GB) | 2003-09-18 | — | — | US | claimed |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG (DE) | 2003-07-10 | — | — | US | claimed |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | PROBIODRUG (DE) | 2003-06-26 | — | — | US | claimed |
| WO-2003015775-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | PROBIODRUG AG (DE) | 2003-02-27 | — | — | WO | claimed |
| WO-2003002596-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | claimed |
| WO-2003002595-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | KMT2A 2238/4885ALOX15 4009/4885BLM 4829/4885 |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | DPP4, DPP3, DPP7 | KMT2A 2168/4885ALOX15 1964/4885BLM 4635/4885 |
| US-20030176357-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | DPP4, DPP3, DPP9 | KMT2A 2898/4885ALOX15 3631/4885BLM 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.